Mundipharma EDO GmbH is part of the Mundipharma global network of privately-owned independent associated companies, which operate in over 120 countries worldwide. We develop therapies for patients around the world with rare and relapsed/refractory (difficult-to-treat) cancer, investigating smart approaches to new cancer treatments from concept through to clinical development and regulatory approval.
Press return to search
/mundipharma